& Pharmaceutical Research
|The rapidly changing
economic, trade and intellectual property scenario, nationally and internationally
poses many challenges including the challenge of becoming leaders and competitors
globally. This necessitates a shift in the approach of pharmaceutical industry
to move away from manufacturing only known drugs through innovative process routes
to discovering and commercialising new molecules. The accumulated knowledge of
traditional medicinal system and large bio-|
| diversity of our country offer
a great advantage to drug industry. However, at present, most of the Indian drug
firms, due to their small size compared to international operators, are not in
a position to invest in a viable new drug development programme - drug development
being a risky, resource intensive & time consuming process. At the same time
several Indian academic institutions and national laboratories have established
impressive infrastructure and developed excellent expertise in selected areas
of drug development. Thus, this is a strong case for industry- institution interaction.
the profound influence of R&D on the prospects and opportunities for the growth
of the Indian Drug Industry, Department of Science and Technology (DST), Government
of India mounted the programme on drug development during 1994-95 for promoting
collaborative R&D in drugs and pharmaceuticals sector with the following specific
- To synergise the strengths of publicly funded R&D
institutions and Indian Pharmaceutical Industry.
- To create an enabling
infrastructure, mechanisms and linkages to facilitate new drug development.
- To stimulate skill development of human resources in R&D for drugs
and pharmaceuticals; and
- To enhance the nation's self-reliance in
drugs and pharmaceuticals especially in areas critical to national health requirements.
January 2004, Government of India established Drug Development Promotion Board
(DDPB) under the administrative control of DST for supporting R&D projects
jointly proposed by industry and academic institutions/ laboratories and to extend
soft loan for R&D to drug industry.
Collaborataive R&D Projects
- supports research in all systems of medicines including setting up of facilities
- supports joint research projects of industry and institution
50 : 50 sharing of financial requirements between industry and institution
- research undertaken by industry is funded 100% by industry
share is supported jointly by government and industry. Capital expenditure: 100%
by government, recurring expenditure: 70% by government and 30% by industry
- DSIR recognition is desirable
for Pharma Industrial R&D Projects
- Loan amount upto 70% of the
- Loan will be an unsecured one carrying a simple interest
of 3% on reducing amount.
- Repayment of the loan will be in 10 annual
equal instalments after the project period.
- Interest during the implementation
period will be amortized and will be payable in maximum of 5 instalments after
the project period along with the instalment of principal amount.
to Industry for Clinical trials for developing drugs for neglected diseases: Any
Indian Pharma Industry including new and small for R & D projects involving
clinical trials (phase-I, II and II) of developing drugs for neglected diseases
like tuberculosis, malaria, kala-azar, filariasis, etc.
programme supports both human and veterinary drug development for all types of
medicinal systems, be it traditional Indian medicinal system or the modern one.
The programme employs a two pronged approach involving exploratory drug design
and drug development on candidate molecules already identified on one hand and
providing a cutting edge to Indian Industry through innovative process for known/generic
drugs as well as crucial intermediates on the other. Some of the areas where support
could be considered are:
(a) any component/stage in the innovation
chain of new drug development
(b) innovative/cleaner process technology for
known drugs/key intermediates, where India has a competitive advantage
chiral synthesis of drugs
(d) resolution of racemic drugs
(f) development of new formulations and standardization/testing of
Can Apply ?
Any Indian company/firm engaged in drug
development manufacturing jointly with:
(a) National laboratory
under CSIR, ICMR, etc.
(b) University department/other academic institution
such as IIT, IISc., etc.
(c) Any other publicly funded R&D Institution
Of The Proposals
Project proposals are first reviewed, in strict
confidence, by an expert in the specific field and then considered by an Expert
Terms and Conditions
agreement amongst the collaborating parties specifying the rights and obligations
and terms and conditions of the DST grant is essential. The terms and conditions
(a) Ownership of intellectual property
generated in the project on agreed terms
(b) Review of the project by a Monitoring
(c) 30% of the recurring expenditure (Institutional
component) to be met by the collaborating industry
for Submitting R&D Projects Under DPRP
Draft Agreement Under DPRP
more information on Drugs & Pharmaceutical Research :
Dr. Neeraj Sharma
Department of Science and Technology
New Delhi-110 016
Telefax : 011-26964781
Email: neerajs at nic dot in
Email: ritub at nic dot
crdurai at rediffmail dot com